Halozyme Therapeutics (NASDAQ: HALO) and Vital Therapies (NASDAQ:VTL) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.
Insider & Institutional Ownership
84.5% of Halozyme Therapeutics shares are owned by institutional investors. Comparatively, 24.3% of Vital Therapies shares are owned by institutional investors. 16.8% of Halozyme Therapeutics shares are owned by insiders. Comparatively, 32.6% of Vital Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
This table compares Halozyme Therapeutics and Vital Therapies’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Halozyme Therapeutics||$146.69 million||17.45||-$103.02 million||($0.68)||-26.44|
|Vital Therapies||N/A||N/A||-$40.96 million||($1.35)||-4.07|
Vital Therapies has lower revenue, but higher earnings than Halozyme Therapeutics. Halozyme Therapeutics is trading at a lower price-to-earnings ratio than Vital Therapies, indicating that it is currently the more affordable of the two stocks.
This table compares Halozyme Therapeutics and Vital Therapies’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk and Volatility
Halozyme Therapeutics has a beta of 2.09, suggesting that its stock price is 109% more volatile than the S&P 500. Comparatively, Vital Therapies has a beta of 5.12, suggesting that its stock price is 412% more volatile than the S&P 500.
This is a breakdown of current ratings and recommmendations for Halozyme Therapeutics and Vital Therapies, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Halozyme Therapeutics presently has a consensus price target of $18.67, suggesting a potential upside of 3.82%. Vital Therapies has a consensus price target of $6.00, suggesting a potential upside of 9.09%. Given Vital Therapies’ stronger consensus rating and higher probable upside, analysts clearly believe Vital Therapies is more favorable than Halozyme Therapeutics.
Vital Therapies beats Halozyme Therapeutics on 8 of the 13 factors compared between the two stocks.
Halozyme Therapeutics Company Profile
Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant. The Company’s development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).
Vital Therapies Company Profile
Vital Therapies, Inc. is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant. The ELAD System is a liver support system containing immortal human liver-derived cells, or VTL C3A cells. The Company initiated a Phase III clinical trial in severe acute alcoholic hepatitis (sAAH), referred to as VTL-308. Its VTL-308 is a randomized, open-label, multicenter, controlled, pivotal study, designed to evaluate the ELAD System in subjects with sAAH. It is based on pre-specified and post-hoc analyses of its VTI-208 phase III clinical trial in alcohol-induced liver decompensation (AILD). The Company’s ELAD System consists of approximately four disposable ELAD C3A cell cartridges.
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.